GILD Live signals | Maximize Profits with Getagraph.com

SELL 4563 min ago

@ $68.43

Issued: 28 Jun 2024 @ 15:51

Return: 0.31%

Previous signal: Jun 28 - 13:12

Previous signal: Buy

Return: -0.33 %

Live Chart Being Loaded With Signals

Commentary (1 Jul 2024 @ 16:00):
Our systems believe the stock currently is undervalued by 0.21% compare to its pairs and should correct upwards.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally...

Stats
Today's Volume	5.14M
Average Volume	7.76M
Market Cap	85.52B
EPS	$-3.34 ( Q1 \| 2024-05-08 )
Next earnings date	( $1.580 ) 2024-08-01
Last Dividend	$0.770 ( 2024-06-14 )
Next Dividend	$0 ( N/A )
P/E	190.67 (Sector) 42.63 (Industry) 0
ATR14	$1.480 (2.16%)

AMGN -0.46%

BIIB -0.02%

GILD 0.04%

GRFS -0.40%

HZNP 0.00%

SNY 2.21%

Insider Trading

Date	Person	Action	Amount	type
2024-06-10	Dickinson Andrew D	Buy	3 639	Common Stock
2024-06-10	Dickinson Andrew D	Sell	1 662	Common Stock
2024-06-10	Dickinson Andrew D	Sell	3 639	Restricted Stock Unit
2024-06-10	Patterson Sandra	Buy	901	Common Stock
2024-06-10	Patterson Sandra	Sell	255	Common Stock

INSIDER POWER
65.97
Last 99 transactions
Buy: 1 409 865 \| Sell: 290 586

Correlation (AI algo v.1.1b): Undervalued: 0.21% $68.78 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: 0.32 (neutral)

Short: 0.47 (neutral)

Signal:(59) Neutral

Gilead Sciences Inc Correlation

10 Most Positive Correlations
NUTX	0.965
PRTA	0.959
TROO	0.955
SINT	0.952
APLD	0.944
INCY	0.943
TRVN	0.939
RNW	0.939
GOVX	0.939
LCFY	0.938

10 Most Negative Correlations
APXI	-0.945
SLMBP	-0.924
BCSA	-0.924
SWAV	-0.921
KINS	-0.917
TAYD	-0.915
SERA	-0.913
FLXS	-0.913
HYAC	-0.912
BOCN	-0.911

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Gilead Sciences Inc Correlation - Currency/Commodity

-0.13
( neutral )

-0.30
( neutral )

0.00
( neutral )

0.35
( neutral )

0.13
( neutral )

-0.42
( neutral )

Gilead Sciences Inc Financials

Annual	2023
Revenue:	$27.12B
Gross Profit:	$21.15B (77.99 %)
EPS:	$4.54

FY	2023
Revenue:	$27.12B
Gross Profit:	$21.15B (77.99 %)
EPS:	$4.54

FY	2022
Revenue:	$27.28B
Gross Profit:	$21.62B (79.26 %)
EPS:	$3.66

FY	2021
Revenue:	$27.31B
Gross Profit:	$20.70B (75.82 %)
EPS:	$4.96

Financial Reports:

No articles found.

Gilead Sciences Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.730 (N/A)	$0.730 (N/A)	$0.750 (N/A)	$0.750 (N/A)	$0.750 (N/A)	$0.750 (N/A)	$0.770 (N/A)	$0.770 (N/A)	$0 (N/A)	$0 (N/A)

Gilead Sciences Inc Dividend Information - Dividend King

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.34 - Stable (13.19%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.430	2015-06-12
Last Dividend	$0.770	2024-06-14
Next Dividend	$0	N/A
Payout Date	2024-06-27
Next Payout Date	N/A
# dividends	37	--
Total Paid Out	$23.03	--
Avg. Dividend % Per Year	3.26%	--
Score	5.37	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.34
Div. Directional Score	7.32	--

Next Divdend (Est)
(2024-09-30)

$0.785 Estimate 74.56 %

Dividend Stability

0.99 Excellent

Dividend Score

5.37

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2015	$1.290	1.36%
2016	$1.840	1.88%
2017	$2.08	2.80%
2018	$2.28	3.08%
2019	$2.52	3.97%
2020	$2.72	4.17%
2021	$2.84	4.72%
2022	$2.92	4.02%
2023	$3.00	3.51%
2024	$1.540	1.85%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Dividend History

Ex Date	Amount	Declaration Date	Record Date	Payment Date
14 Jun 2024	$0.770	25 Apr 2024	14 Jun 2024	27 Jun 2024
14 Mar 2024	$0.770	01 Feb 2024	15 Mar 2024	28 Mar 2024
14 Dec 2023	$0.750	07 Nov 2023	15 Dec 2023	28 Dec 2023
14 Sep 2023	$0.750	03 Aug 2023	15 Sep 2023	28 Sep 2023
14 Jun 2023	$0.750	27 Apr 2023	15 Jun 2023	29 Jun 2023
14 Mar 2023	$0.750	02 Feb 2023	15 Mar 2023	30 Mar 2023
14 Dec 2022	$0.730	27 Oct 2022	15 Dec 2022	29 Dec 2022
14 Sep 2022	$0.730	02 Aug 2022	15 Sep 2022	29 Sep 2022
14 Jun 2022	$0.730	28 Apr 2022	15 Jun 2022	29 Jun 2022
14 Mar 2022	$0.730	01 Feb 2022	15 Mar 2022	30 Mar 2022
14 Dec 2021	$0.710	28 Oct 2021	15 Dec 2021	30 Dec 2021
14 Sep 2021	$0.710	29 Jul 2021	15 Sep 2021	29 Sep 2021
14 Jun 2021	$0.710	27 Apr 2021	15 Jun 2021	29 Jun 2021
12 Mar 2021	$0.710	04 Feb 2021	15 Mar 2021	30 Mar 2021
14 Dec 2020	$0.680	28 Oct 2020	15 Dec 2020	30 Dec 2020
14 Sep 2020	$0.680	30 Jul 2020	15 Sep 2020	29 Sep 2020
11 Jun 2020	$0.680	29 Apr 2020	12 Jun 2020	29 Jun 2020
12 Mar 2020	$0.680	03 Feb 2020	13 Mar 2020	30 Mar 2020
12 Dec 2019	$0.630	23 Oct 2019	13 Dec 2019	30 Dec 2019
12 Sep 2019	$0.630	29 Jul 2019	13 Sep 2019	27 Sep 2019

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Diamond	2024-09-16	Monthly	14	15.03%	9.60
DMLP	Dividend Diamond	2024-04-26	Quarterly	22	10.71%	9.35
OXSQ	Dividend Diamond	2024-09-16	Monthly	21	12.73%	9.02
ARLP	Dividend Royal	2024-05-07	Quarterly	26	9.67%	8.87
PNNT	Dividend Royal	2024-06-14	Monthly	18	9.49%	8.82
MFIC	Dividend Royal	2024-06-11	Quarterly	21	10.89%	8.79
SPOK	Dividend Royal	2024-05-23	Quarterly	20	8.73%	8.72
PSEC	Dividend Royal	2024-06-25	Monthly	21	9.03%	8.65
SBLK	Dividend Royal	2024-06-06	Quarterly	17	13.10%	8.63
GBDC	Dividend Royal	2024-11-29	Bi-Monthly	15	8.53%	8.62

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0176	1.500	9.65	10.00	[0 - 0.5]
returnOnAssetsTTM	0.00860	1.200	9.71	10.00	[0 - 0.3]
returnOnEquityTTM	0.0232	1.500	-0.854	-1.281	[0.1 - 1]
payoutRatioTTM	7.91	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	1.079	0.800	9.61	7.68	[1 - 3]
quickRatioTTM	0.824	0.800	9.86	7.89	[0.8 - 2.5]
cashRatioTTM	0.363	1.500	9.10	10.00	[0.2 - 2]
debtRatioTTM	0.448	-1.500	2.54	-3.81	[0 - 0.6]
interestCoverageTTM	9.40	1.000	7.63	7.63	[3 - 30]
operatingCashFlowPerShareTTM	6.80	2.00	7.73	10.00	[0 - 30]
freeCashFlowPerShareTTM	6.34	2.00	6.83	10.00	[0 - 20]
debtEquityRatioTTM	1.436	-1.500	4.25	-6.38	[0 - 2.5]
grossProfitMarginTTM	0.777	1.000	0.382	0.382	[0.2 - 0.8]
operatingProfitMarginTTM	0.331	1.000	5.37	5.37	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.337	1.000	9.24	9.24	[0.2 - 2]
assetTurnoverTTM	0.488	0.800	-0.0824	-0.0659	[0.5 - 2]
Total Score				10.30

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	176.77	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.0232	2.50	-0.549	-1.281	[0.1 - 1.5]
freeCashFlowPerShareTTM	6.34	2.00	7.89	10.00	[0 - 30]
dividendYielPercentageTTM	4.43	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.80	2.00	7.73	10.00	[0 - 30]
payoutRatioTTM	7.91	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	-9.55	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.309	1.000	4.78	0	[0.1 - 0.5]
Total Score				4.34

Gilead Sciences Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Gilead Sciences Inc

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.